Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver

Use of at least one antagonist adenosine A2A receptor for the preparation of a medicine for treating or preventing hepatic fibrosis, cirrhosis and / or fatty liver with complications, wherein the antagonist adenosine A2A receptor is selected from from the group consisting of 2-fenilaminoadenosina, 2-p-2-carboxietilfenilamino- 5 '' - N-ethylcarboxamido-adenosine, 5-N-ethylcarboxamido-adenosine, 5 '' - N-ciclopropiladenosina, 5''N-metilcarboxamidoadenosina, 8- (3-chlorostyryl) caffeine, PD-1259444, 1,3-dipropyl-phenylxanthine and 4- {2- [7-amino-2- (2-furyl) [1,2,4] -triazolo [2, 3-a] - [1,3,5] triazin-5-ylamino] ethyl} phenol (ZM 241385), 8-estirílicos derivatives of 1,3-7- alkylxanthines of the following formula: (See formula) in R1 and R3 are methyl, ethyl, propyl or allyl; R7 is H, methyl, or C1-C8 alkyl; R is hydrogen; and compounds of the following formula: wherein Y is m-Br or p-SO3H (See formulas)